All In Biotech

Drug Trial Radar · NCT07299422

A Study of SHR-2173 in Participants With Systemic Lupus Erythematosus

A Multi-center, Randomized, Double-blind, Placebo-controlled Phase II Clinical Study to Evaluate the Efficacy and Safety of SHR-2173 Injection in Patients With Systemic Lupus Erythematosus

Last checked: Nov 19, 2026Latest source record: Sep 29, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 248 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

248

Planned (sponsor's estimate)

Start

Apr 3, 2026

Primary completion

Mar 2028

Study completion Nov 2028

Sponsor

Sponsor type
Industry
First posted
Dec 23, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is a randomized, double-blind, multi-center, placebo-controlled Phase II clinical trial to evaluate the efficacy and safety of SHR-2173 in adult participants with active Systemic Lupus Erythematosus (SLE), including a 4-week screening period, a 24-week core treatment period, a 24-week maintenance treatment period, and a 12-week safety follow-up period. Approximately 245 SLE patients will be included.

Conditions

  • Systemic Lupus Erythematosus

Interventions

  • SHR-2173 InjectionDrug

    SHR-2173 injection in different doses.

  • SHR-2173 Injection PlaceboDrug

    SHR-2173 injection placebo.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. The proportion of participants achieving Systemic Lupus Erythematosus Responder Index-4 (SRI-4) at Week 24.Time frame: At Week 24.

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • Chinese Academy of Medical Sciences, Peking Union Medical College Hospital

    Beijing, Beijing Municipality, China · Recruiting

  • Renji Hospital Affiliated to Shanghai Jiao Tong University School of Medicine

    Shanghai, Shanghai Municipality, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.